Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 30 Mar 2017 Status changed from active, no longer recruiting to completed.
- 08 Jul 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 08 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.